Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.
Continue reading→

Peer-reviewed study in the Journal of Clinical Microbiology reports more than 90% sensitivity across disease stages and improved detection during the early diagnostic “gray zone.” Continue reading→

Two-year project will use new approach methodologies to examine sex-specific differences in the cellular biology of Parkinson’s disease.Continue reading→

Method could someday be used to assess treatment responseContinue reading→

Large analysis of normal and cancer tissues offers a new explanation for why cancer cells carry far more genetic mutations than healthy cellsContinue reading→

The National Center to Accelerate Cures Opens in Baltimore, Backed by $3 Million in Congressionally Directed Funding Secured by Sens. Van Hollen and AlsobrooksContinue reading→

Researchers, clinicians and other experts from across the University of Arizona and Banner Health are bringing together expertise from medicine, engineering, pharmacy, science and other disciplines to tackle major health challenges and move promising health discoveries closer to patient care.Continue reading→

University of Arizona leaders joined Phoenix Mayor Kate Gallego, members of the Arizona Board of Regents, Arizona health and community partners, and the construction team Wednesday afternoon to celebrate the placement of the final structural beam atop the new Medical Innovations Building, marking a major milestone in the university’s efforts to advance groundbreaking healthcare research.Continue reading→

• Phase 3 trial results earn Rapid Communication status, underscoring the importance of the ROADS findings in clinical practice, with the trial authors endorsing GammaTile as a new standard-of-care option for newly diagnosed operable brain metastases1
• GammaTile demonstrated 98.7% local tumor control by 12 months, compared to 84.6% for standard-of-care, reducing the risk of surgical bed recurrence at 12 months by more than 90% (HR: 0.07, 95% CI: 0.01–0.56; p=0.012)1*
• GammaTile is estimated to reduce the combined risk of tumor recurrence or death by more than 50% compared to standard-of-care (HR: 0.48, 95% CI: 0.30-0.76, p=0.002)1
• The median overall survival for patients who received GammaTile was longer than that of patients who received standard-of-care: median overall survival was 42.5 months compared to 17.6 months with standard-of-care (HR: 0.59, 95% CI: 0.37-0.96, p=0.032)1
• Treatment with GammaTile did not increase the risk of side effects compared to standard-of-care.1

Continue reading→

Former House Majority Leader and global business executive brings decades of public policy and private-sector experience to lead the industry at a pivotal moment for American medical innovationContinue reading→